LDL-C and ASCVD Risk Reduction: The Utility of PCSK9 Inhibitors (Home Study)

Activity Preview

Cardiovascular disease is becoming more manageable—and preventable. Important progress has included the American College of Cardiology (ACC) 2016 Expert Consensus Decision Pathway on the management of cholesterol, the National Lipid Association (NLA) 2017 recommendations that frame the use of the two approved PCSK9 inhibitors.

This archived webinar will outline the role of PCSK9 inhibitors in cardiovascular risk reduction and provide guidance regarding the identification of patients who would be appropriate for treatment with these medications.

Learning Objectives

At the completion of this activity, the pharmacist will be able to:

1. Discuss the evidence evaluating the efficacy and safety of PCSK9 inhibitors in patients with dyslipidemia.
2. Describe recommendations for appropriate use of PCSK9 inhibitors based on ACC and NLA recommendations.
3. Develop monitoring strategies to assess the efficacy and toxicity of PCSK9 inhibitors.

Activity Type: Application-based

Target Audience: Pharmacists

Learning Level: Level 2

Accreditation Information 

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This home study CPE activity is approved for 1.0 contact hour of CPE credit (0.10 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-17-241-H01-P.

To obtain credit for "LDL-C and ASCVD Risk Reduction: The Utility of PCSK9 Inhibitors (Home Study)," watch the achived webinar, complete the assessment with a grade of 70% or better, complete the evaluation, and then CLAIM credit. Participants will need to have a valid pharmacist.com username and password to claim credit. After your credit has been claimed, please visit CPE monitor for your transcript.  

APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education examination. Please note that you will not be permitted to submit the examination a third time. All exam questions are randomized and may not appear in the same order as printed. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. 

Initial Release Date: October 18, 2017

Expiration Date: October 18, 2020

Development

"LDL-C and ASCVD Risk Reduction: The Utility of PCSK9 Inhibitors (Home Study)" is an archived, recorded webinar and educational activity for pharmacists developed by the American Pharmacists Association.                                                                                   

Disclosures

Joseph Saseen, PharmD, BCPS, BCACPand APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, please visit the APhA website at: www.pharmacist.com/apha-disclosures.  Conflicts of interest have been resolved through content review by Helen Sairany, PharmD, BCACP, Associate Director of Content Development at the American Pharmacists Association. 

Activity Fee

There is no fee for APhA Members and $129 for non-members. This online educational activity is available exclusively to APhA members for the first 30 days of release, as a free member benefit. Thereafter, non-members can purchase this activity at a cost of $129.

System Requirements

Computer and Internet access is required to complete this activity.  Please visit our website to view the Technology System Requirements to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-17-241-H01-P 0.1 CEUs October 18, 2017 - October 18, 2020